Cao Xi-liang, Gao Jiang-ping, Han Gang, Tang Jie, Hong Bao-fa
Department of Urology, General Hospital of People's Liberation Army, Beijing 100853, China.
Zhonghua Wai Ke Za Zhi. 2006 Mar 15;44(6):372-5.
To evaluate the detection of prostate cancer in different prostate specific antigen (PSA) level and the predict value of PSA, digital rectal examination (DRE), transrectal ultrasound scan (TRUS) and PSA density (PSAD).
The clinical data of 634 cases who had underwent transrectal ultrasound guided systematic sextant prostate biopsies between April 1996 to December 2002 due to being suspicious of prostate cancer were retrospectively analyzed. The detection of prostate cancer in different PSA groups, namely PSA < or = 4.0, 4.1-, 10.1-, > 20.0 microg/L, and the predict values of PSA, DRE, TRUS and PSAD were statistically analyzed using t test, chi2 test and logistic regression analysis.
The rates of prostate cancer detection in different PSA groups were 11.6%, 26.8%, 39.8% and 68.6%, respectively. The higher the PSA, the higher the rate of prostate cancer detection, the same was the positive predictive value of DRE and TRUS. The sensitivity and specificity of PSA > 4.0 microg/L were 93.0% and 33.0%, and the efficiency of DRE and TRUS were very low. Logistic regression analysis indicated that PSAD was the most risk factor of prostate cancer in the group of PSA 4.1-20.0 microg/L (OR = 687.09 +/- 646.96, P = 0.000).
The rates of prostate cancer detection in different PSA groups are different compared with other countries. The screening roles of DRE and TRUS are dependent on PSA level. Utilization of the screening protocol which to stratify cases into three PSA groups, namely PSA < or = 4.0, 4.1 - 20.0, > 20.0 microg/L, can elevate the positive rate of prostate biopsies without sacrificing cancers detected.
评估不同前列腺特异性抗原(PSA)水平下前列腺癌的检测情况以及PSA、直肠指检(DRE)、经直肠超声扫描(TRUS)和PSA密度(PSAD)的预测价值。
回顾性分析1996年4月至2002年12月间因怀疑前列腺癌而接受经直肠超声引导下系统六分区前列腺穿刺活检的634例患者的临床资料。对不同PSA组(即PSA≤4.0、4.1 -、10.1 -、>20.0μg/L)中前列腺癌的检测情况以及PSA、DRE、TRUS和PSAD的预测价值进行t检验、χ²检验和逻辑回归分析。
不同PSA组前列腺癌的检出率分别为11.6%、26.8%、39.8%和68.6%。PSA越高,前列腺癌检出率越高,DRE和TRUS的阳性预测值也越高。PSA>4.0μg/L的敏感性和特异性分别为93.0%和33.0%,DRE和TRUS的效能很低。逻辑回归分析表明,在PSA 4.1 - 20.0μg/L组中,PSAD是前列腺癌的最危险因素(OR = 687.09±646.96,P = 0.000)。
与其他国家相比,不同PSA组的前列腺癌检出率有所不同。DRE和TRUS的筛查作用取决于PSA水平。采用将病例分为三个PSA组(即PSA≤4.0、4.1 - 20.0、>20.0μg/L)的筛查方案,可提高前列腺穿刺活检的阳性率,且不影响癌症的检出。